Alpine Immune Sciences Announces Scientific Presentations at 60th American Society of Hematology Annual Meeting and Exposition

SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy
company focused on developing innovative treatments for cancer,
autoimmune/inflammatory, and other diseases, today announced two
upcoming poster presentations at the 60th American Society of
Hematology (ASH) Annual Meeting and Exposition to be held December 1-4,
2018 in San Diego, CA.

60th ASH Annual Meeting and Exposition

  • Abstract Title: Therapeutic Candidate ALPN-101, a Dual
    ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft
    Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces
    Disease Activity in a Mouse Model of Hemophagocytic
    Lymphohistiocytosis (HLH)
  • Session Name: 701. Experimental Transplantation: Basic Biology,
    Pre-Clinical Models: Poster I
  • Publication Number: 2037
  • Abstract Title: “Switch” Transmembrane Immunomodulatory
    Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains
    (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance
    the Activity of TCR-Engineered T Cells
  • Session Name: 703. Adoptive Immunotherapy: Poster I
  • Publication Number: 2052

Both posters will be available in Hall GH of the San Diego Convention
Center on Saturday, December 1, 2018 from 6:15 p.m. PT – 8:15 p.m. PT.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of
functional immune therapeutics. Alpine is the first company employing
directed evolution to create potentially powerful multifunctional
immunotherapies to improve patients’ lives. Supported by promising
preclinical data, we aim to have two programs in the clinic in 2019. The
first, ALPN-101 for autoimmune/inflammatory diseases, is a dual
ICOS/CD28 antagonist, engineered to reverse pathogenic immune responses.
The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and
PD-L1-dependent CD28 T cell costimulator intended to combine checkpoint
inhibition with a necessary costimulation signal – an approach currently
absent from approved checkpoint therapies. Alpine is backed by
world-class research capabilities, a highly-productive scientific
platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not based on
historical fact, and include statements regarding Alpine’s platform
technology and potential therapies. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar
expressions among others. These forward-looking statements are based on
current assumptions that involve risks, uncertainties and other factors
that may cause actual results, events or developments to be materially
different from those expressed or implied by such forward-looking
statements. These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: Alpine’s discovery-stage and
pre-clinical programs may not advance into the clinic or result in
approved products on a timely or cost-effective basis or at all; Alpine
may not achieve additional milestone payments pursuant to its
collaborations; the impact of competition; adverse conditions in the
general domestic and global economic markets; as well as the other risks
identified in Alpine’s filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date
hereof and Alpine undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance on
such forward-looking statements.

“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,”
“vIgD” and the Alpine logo are registered trademarks or trademarks of
Alpine Immune Sciences, Inc. in various jurisdictions.

Contacts

Investor Relations:
Pure Communications
Courtney Dugan,
212-257-6723
cdugan@purecommunications.com
or
Media
Relations:
Pure Communications
Jennifer Paganelli, 347-658-8290
jpaganelli@purecommunications.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.